Teva and Sanofi Report Positive Results for Gut Disease Drug Duvakitug
Translated & summarized from Bizportal by baba
Teva and Sanofi reported positive results from a Phase 2b trial of Duvakitug, an experimental drug for ulcerative colitis and Crohn's disease. The drug showed sustained efficacy and a favorable safety profile in patients who responded to initial treatment. Duvakitug targets the TL1A protein and is now in Phase 3 trials. The collaboration has already generated $1 billion for Teva, with potential for more as development progresses.
The story in 6 lines · by baba
- Teva and Sanofi's experimental drug Duvakitug showed sustained efficacy in a Phase 2b trial for gut diseases.
- The drug maintained improved conditions for patients over 44 weeks in the maintenance phase.
- Positive clinical remission and endoscopic response rates were observed in both ulcerative colitis and Crohn's patients.
- Duvakitug targets the TL1A protein, potentially impacting inflammation and disease progression.
- The drug is now in four Phase 3 clinical trials, with continued development dependent on outcomes.
- Teva has already received $1 billion from Sanofi as part of their collaboration agreement.
Teva Pharmaceuticals and Sanofi have announced positive outcomes from a Phase 2b clinical trial of their experimental drug, Duvakitug, intended for treating ulcerative colitis and Crohn's disease. The data, presented at a medical conference in Barcelona, indicated that patients who responded to the initial 14-week treatment maintained their improved condition for an additional 44 weeks, extending the total treatment observation to 58 weeks.
The trial involved 130 patients who responded to the initial therapy, with 72 diagnosed with ulcerative colitis and 58 with Crohn's disease. Participants received either 450mg or 900mg of Duvakitug via subcutaneous injection every four weeks. Among ulcerative colitis patients, 58% achieved clinical remission at week 44 of the maintenance phase with the higher dose, compared to 47% with the lower dose. Clinical response rates were 87% and 82% respectively. Endoscopic improvements were seen in 63% of high-dose patients versus 59% of low-dose patients.
For Crohn's disease patients, the higher dose resulted in 55% achieving endoscopic response, compared to 41% with the lower dose. Clinical remission rates were 84% for the high dose and 81% for the low dose. The companies reported that the drug's safety profile remained consistent with earlier trial phases, with no new safety concerns identified. While key efficacy data was previously released in February, the current findings provide further detail on treatment response and biological markers.
It is important to note that the maintenance phase included only patients who initially responded to the treatment, excluding a placebo group. Therefore, these results demonstrate sustained efficacy in a selected patient population but do not yet confirm the drug's effectiveness across all patients. Duvakitug targets the TL1A protein, which is involved in inflammatory processes and scar tissue formation in the gut. The companies are investigating whether inhibiting this protein can alleviate symptoms and potentially impact disease progression.
Duvakitug is currently in four Phase 3 clinical trials, two for ulcerative colitis and two for Crohn's disease, with potential expansion to other inflammatory conditions. The drug has not yet been approved for marketing, and its future development hinges on the outcomes of these advanced trials. The collaboration with Sanofi, initiated in October 2023, has already provided Teva with $1 billion in payments, with up to an additional $500 million possible based on future milestones. The companies will share global development costs and profits/losses, with Sanofi handling commercial activities in North America and parts of Asia, and Teva in Europe, Israel, and other regions.